CVS Just Made a Big Change After Closing Its $69 Billion Aetna Deal. Here's What That Could Mean




 

With its $69 billion mega-merger with Aetna officially closed, pharmacy giant CVS is making one of its first major shakeups in its business structure after combining forces with the insurer, offering a new option to pass on 100% of drug rebates to its health plan sponsors (i.e., companies or organizations that sponsor health benefits for their employees and members).

One of CVS' most important factions is its Caremark arm-one of the big three pharmacy benefits mangers (PBMs) alongside Express Scripts and Optum's PBM unit that serve as (largely opaque) gatekeepers and middlemen in the drug pricing supply chain. PBMs negotiate discounts with drug makers to their products' list prices and take a cut from those rebates.

However, these discounts don't necessarily make it down the supply chain to health plan sponsors or consumers themselves. That's drawn increasing ire from lawmakers and the Trump administration, who have recently pointed to PBMs' role in propping up drug prices as an issue that needs to be addressed.

CVS' new "Guaranteed Net Cost" pricing option would reportedly tackle some of these concerns, including a lack of transparency in list-versus-net price negotiations, by ensuring a pass through of drug rebates to plan sponsors. It would apply to retail, mail order, and specialty pharmacy prescriptions alike, according to CVS.

"We see a real opportunity to offer clients a simpler economic model that leverages proven PBM cost management strategies to provide predictable drug costs," said Derica Rice, president of CVS Caremark, in a statement announcing the new option.

To be clear, while this is a significant change in business structure for CVS-Aetna, the 100% rebate pass through may not ultimately reach consumers, or at least not in full. The decision on whether or not to do that will rely on whether or not the plan sponsors (at first, employer-sponsored health plans, and potentially government health programs in the future) decide to further pass through such discounts to their beneficiaries at the point of sale.

But it is a notable first step in changing the basic relationship between drug makers, PBMs, and plan sponsors. And that likely has a lot to do with the Aetna merger. Mark Bertolini, CEO of Aetna prior to the CVS sale, has argued the two firms' vertical integration will allow for these precise sorts of changes, as well as shifts in the very way that primary care and chronic disease management is developed on a community level.

"Build a marketplace for a community around health," Bertolini said of the merger's possibilities during Fortune's Brainstorm Health conference this past March. "Why not eliminate benefits as a notion? Let's say, we're going to do what we can in the community to help you, we're going to build a supply chain, and that supply chain is going to provide you a service at a better cost."

Subscribe to Brainstorm Health Daily, our newsletter about the most exciting health innovations.

COMMENTS

More Related News

3 Top Tech Stocks to Buy in February
3 Top Tech Stocks to Buy in February

If you're in the market for technology stocks, these are the ones worth your attention right now.

American Water Works' Q4 Earnings Meet Expectations
American Water Works' Q4 Earnings Meet Expectations

The country's largest publicly traded water utility closed out a strong year with so-so fourth-quarter results.

Nearly 50% of Younger Workers Think They
Nearly 50% of Younger Workers Think They'll Be Ready to Retire Between 45 and 65. Are They Right?

It's a lofty goal. But is it attainable?

What Is a Traditional IRA? Rules, Limits and More
What Is a Traditional IRA? Rules, Limits and More

Individual retirement accounts (IRAs) are important vehicles for Americans to prepare for the day they stop working. This is especially true for those without access to a workplace retirement plan like a 401(k), though you also can use an IRA … Continue reading ->The post What Is a Traditional IRA

CVS Predicts an Ugly 2019 After Closing $68 Billion Aetna Deal
CVS Predicts an Ugly 2019 After Closing $68 Billion Aetna Deal

Key InsightsThe company is trying to set low expectations after the Aetna deal's November closure. Chief Executive Officer Larry Merlo called 2019 a "year of transition" in a statement and said CVS would need to "address the impact of certain headwinds that are having a disproportionate impact in 2019

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Economy

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.